Most fragrance launches in France and Germany do not fail in the formula — they fail in the gap between what the scent actually does on skin and what the brand tells consumers it will do. A wear-test panel is the cheapest way to close that gap before you commit to packaging, artwork and marketing copy. This guide explains how to design a panel that produces usable, defensible performance data for a French or German launch, and what documentation you should request from your fragrance manufacturer before the first sample is approved.
Why a wear-test panel decides a French or German launch
In both markets, “longevity” and “projection” are the words consumers use to judge whether a fragrance was worth the money. But the two markets do not read performance the same way, and your panel design has to reflect that.
- France is polarised. Prestige retail rewards EDP and extrait with real presence, while a parallel niche and “skin scent” culture rewards low-projection, intimate fragrances. A single panel design that only tests “how strong is it” will mislead you in one direction or the other.
- Germany is a claim-sensitive, documentation-driven market. Retail buyers and consumers respond well to specific, substantiated language and poorly to vague superlatives. If your copy says something measurable, expect it to be scrutinised.
- Both are EU markets, which means your performance claims sit inside a compliance framework: a Responsible Person, a CPSR, a PIF, CPNP notification and fragrance-allergen labelling under the updated rules of Regulation (EU) 2023/1545. Panel data does not replace any of that — it protects your marketing copy.
- Skin, climate and expectation all move the result. The same formula can read as “present for hours” on one panelist and “gone in two” on another. That variance is exactly what a structured panel measures and what a single number in your copy cannot capture.
A practical red line from the outset: do not promise a uniform “X hours of longevity” figure. Publish graded performance language that your panel data supports, and explain that skin type, climate and application affect perception.
Three decisions to lock before you recruit a single panelist
Decision 1 — What performance tier are you actually selling?
Define the target before testing, or the data will be unusable. Typical tiers:
- Intimate / skin scent — close-wearing, low projection, marketed on texture and intimacy. Common in French niche positioning.
- Balanced everyday EDP — noticeable for the first hours, settles into a personal scent bubble. The safest commercial tier for a first launch.
- High projection / statement — deliberate sillage, usually extrait or high-concentration EDP, with higher risk of “too much” complaints in office contexts.
Write the tier down, and write the acceptance criteria for it. “Panel mean intensity at 6 hours ≥ target benchmark mean, with no more than X% of panelists rating below 3/7” is a usable criterion. “Should last long” is not.
Decision 2 — Which benchmark are you testing against?
Absolute scores are noise. Every panel should include one or two commercial benchmarks — a reference fragrance your target consumer already knows, in the same family and price tier — plus an internal standard sample (a frozen reference of your approved formula) for batch-to-batch comparison later.
Decision 3 — Which claims will you actually print?
Test what you intend to say. If the copy will reference freshness at the opening, test the first 15 minutes. If it will reference all-day presence, test at 6 and 8 hours. If you are considering “clinically tested” or “dermatologist tested”, stop and check the rules first: those claims require that genuine human or clinical testing occurred, or genuine dermatologist involvement, and they are subject to market review. They are not copy flourishes.
Panel design parameter sheet
| Parameter |
Recommended setting |
Why it matters |
Evidence output |
| Panel size |
20–30 for screening and direction; 50–100+ if the data will support an external claim |
Small panels find direction, not statistical confidence |
Recruitment log and final N per cell |
| Recruitment |
Local panelists in France / Germany matching your buyer profile; include both genders if the scent is unisex |
Perfume literacy and category vocabulary differ by market |
Screening questionnaire and demographic summary |
| Entry screening |
Exclude smokers, anosmia, heavy daily fragrance wearers unless that is your target, and anyone with active skin irritation |
Reduces noise and dermatitis risk |
Signed consent and eligibility record |
| Application protocol |
Fixed dose and site (e.g. 2 sprays on each inner forearm or one spray on neck), same time of day, same distance |
Dose and site dominate perceived intensity |
Written protocol version and training record |
| Panelist preparation |
No fragrance, scented lotion or strongly scented shampoo on test day; allow washout between products |
Cross-contamination is the most common source of false positives |
Pre-test instruction sheet and compliance check |
| Blinding and order |
Blind-coded samples, randomised or balanced order, benchmark hidden |
Prevents brand and price bias |
Coding sheet and randomisation record |
| Timepoints |
0–15 min, 1 h, 3 h, 6 h, 8 h (add 12 h only if the tier justifies it) |
Separates opening impact from dry-down performance |
Time-stamped scoring sheets |
| Environment |
Recorded temperature and humidity; ideally one round in a warm/humid condition if your logistics run through hot seasons |
Heat changes projection and perceived strength |
Environment log per session |
| Scoring dimensions |
Intensity, projection, longevity, liking, naturalness of dry-down, “would wear again” |
Gives you copy-ready language, not just a number |
Raw scored dataset |
| Analysis |
Mean, spread and % below threshold versus benchmark; segment by gender and age band |
Prevents a good average hiding a bad tail |
Summary report with charts |
Blotter testing and skin wear testing are not interchangeable
- Blotter (test-strip) testing is your fast screening tool. It checks opening impact, note progression and whether the dry-down turns sour, flat or harsh. It is cheap, repeatable and blind-friendly.
- Skin wear testing is your decision tool. Skin chemistry, temperature and sebum change both projection and longevity, and no blotter can predict how a fragrance behaves on a French consumer in a heated office or a German commuter in winter.
- Use both, in that order. Kill weak submissions on blotter, then spend panel budget on the two or three survivors plus your benchmark.
- Describe the scent in consumer language. A panel that only produces numbers misses a key commercial question: can a shopper understand this fragrance in three seconds on a product page or in a store?
The EU documentation pack your panel must fit inside
- Responsible Person established in the EU — named on the label and in the technical file. Evidence: RP agreement and label artwork.
- CPSR and PIF — product safety report and product information file, referencing the exact formula version tested. Evidence: CPSR signed by a qualified safety assessor, PIF index.
- CPNP notification — before placing on the EU market. Evidence: submission confirmation.
- GMP / ISO 22716 — manufacturing site certification. Evidence: current certificate with validity dates and scope.
- Fragrance allergen declaration — the full allergen list matched to the current EU labelling requirements, including the transition deadlines introduced by Regulation (EU) 2023/1545. Evidence: allergen declaration sheet cross-checked line by line against the printed label.
- IFRA conformity statement — with the Standards version explicitly cited. Evidence: certificate naming the version and the product category.
- Stability and packaging compatibility — including heat exposure and transport simulation. Evidence: stability protocol and report, plus compatibility report covering pump, gasket, coating and label adhesive.
- Microbiology where applicable — relevant for water-based mists and emulsified formats; standard alcohol-based fragrances follow a different risk profile.
- Batch documentation — COA and SDS per batch, with INCI matching the CPSR exactly. Evidence: batch record and COA for the production lot, not just the lab pilot.
Timeline: fast path versus standard path
| Phase |
Buyer action |
Manufacturer / lab action |
Evidence produced |
| 1. Brief and screening (week 1–2) |
Lock performance tier, benchmark and claim list |
Submit 3–5 mods on blotter; narrow to 2–3 |
Blotter evaluation sheet; narrowed shortlist |
| 2. Wear-test round 1 (week 3–4) |
Approve protocol, recruit local panel, book venue |
Supply blind-coded samples and benchmark |
Panel protocol, raw dataset, summary report |
| 3. Fine-tune (week 5–7) |
Decide on one formula direction |
Adjust concentration or structure; repeat targeted wear test |
Revised formula version and comparison report |
| 4. Packaging and stability (week 6–10, parallel) |
Lock bottle, pump, cap, label stock |
Run compatibility and stability, including heat and transport |
Compatibility report, stability report |
| 5. Compliance and artwork (week 8–12) |
Approve label copy and language versions |
Finalise CPSR, PIF, allergen declaration, CPNP |
Signed CPSR, PIF index, CPNP confirmation |
| 6. Pilot and handoff (week 12–16) |
Approve pilot against the frozen standard sample |
Produce pilot batch; issue batch documents |
Pilot COA, SDS, retained standard sample |
Fast path: you may compress phases 3 and 5 by limiting the range to one or two SKUs, using stock bottles and pre-approved label templates, and running stability in parallel with panel round 1. Do not compress the wear test itself, the stability duration, or the CPSR/CPNP steps — those are the three places where speed converts directly into recall or relabelling cost.
Standard path: add a second wear-test round with a fresh panel, a warm-condition test round, and a 2ml discovery or 10ml travel format tested alongside the 50ml. The extra round typically adds three to four weeks and materially reduces the risk of a launch criticised for weak projection.
Failure modes to design out before the pilot
1. “It disappears after two hours”
- Symptom: reviews cite weak longevity despite a prestige price point.
- Root cause: fragrance structure with a fast-fading top, low concentration for the tier, skin-type variation, or consumers anchored to an unrealistic expectation set by marketing.
- Prevention: define the performance tier up front, test against a benchmark, and write copy that describes the tier rather than a fixed number of hours.
- What to request from the factory: wear-test report with timepoint data, comparison against benchmark, and the concentration and formula version tested.
2. Influencer promise versus product reality
- Symptom: complaints that the fragrance is “weak” or has “no projection”, traced back to creator content rather than the product.
- Root cause: creators amplified performance language the brand never tested or approved.
- Prevention: issue a creator brief with approved performance wording tied to the panel report, and a short list of phrases that are off-limits.
- What to request from the factory: a one-page performance summary you can hand to creators, plus written confirmation of the claims the data supports.
3. Packaging compatibility failure
- Symptom: leakage in transit, sticky residue on the collar, pump that sputters or delivers an inconsistent dose, coating or print lifting, label edge curling, or a scent that shifts after two months in the bottle.
- Root cause: pump gasket or elastomer incompatible with the alcohol/fragrance concentrate, viscosity and dose mismatch, plating or decoration reacting with the juice, or adhesive chosen for the wrong surface energy.
- Prevention: test the exact bottle, pump, cap and label combination with the final formula, not a generic fill; include a heat and transport simulation.
- What to request from the factory: packaging compatibility report naming each component and supplier, plus a stability report covering upright and inverted storage at elevated temperature.
4. Documentation mismatch
- Symptom: the printed INCI or allergen list does not match the CPSR and the PIF; a retailer or authority query stalls the listing.
- Root cause: the formula was revised after the CPSR was issued, or labelling was updated without reissuing the safety documentation.
- Prevention: version-control the formula, CPSR and artwork as a single package, and re-verify the allergen list against the printed label before print approval.
- What to request from the factory: a document cross-reference sheet linking formula version, CPSR version, PIF index, allergen declaration and label artwork revision.
5. Panel data collected in the wrong market
- Symptom: the fragrance performs well in internal review but gets “too strong” or “too light” feedback in France or Germany.
- Root cause: the panel was internal, small, or recruited in a different climate and culture from the launch market.
- Prevention: recruit local panelists, run the questionnaire in the local language, and test at least one scenario realistic for that market.
- What to request from the factory: panel composition record and the questionnaire in the local language.
6. Claims outrunning the evidence
- Symptom: copy states “clinically tested”, “dermatologist tested” or a natural-origin percentage that cannot be defended.
- Root cause: claims written by marketing after testing had already been scoped, with no evidence file behind the words.
- Prevention: build a claims matrix before copywriting: each claim, its minimum truth requirement, the evidence, and who signed off.
- What to request from the factory: claims substantiation file with the underlying test reports referenced by claim.
Copy-paste brief to send to your fragrance manufacturer
- Confirm the target market pair (France and/or Germany) and the launch channel.
- State the performance tier in one sentence, with written acceptance criteria.
- Share the benchmark fragrances you want tested alongside.
- Request three to five blotter submissions before any panel spend.
- Lock the wear-test protocol: dose, sites, timepoints, environment, scoring scale.
- Confirm panel size, recruitment criteria and language of the questionnaire.
- Require blind coding and randomised order, with the benchmark hidden.
- Ask for raw data as well as the summary report.
- Provide a retained standard sample from the approved formula.
- Attach the full EU documentation list: RP, CPSR, PIF, CPNP, GMP, IFRA statement, allergen declaration.
- Request the allergen declaration cross-checked against the printed label artwork.
- Lock bottle, pump, cap and label before the pilot run.
- Request a packaging compatibility report naming every component supplier.
- Include heat and transport simulation in the stability scope.
- Approve a claims matrix with evidence owner and sign-off per claim.
- Brief creators using only wording the panel data supports.
- Schedule pilot approval against the standard sample, not against memory.
- Confirm final documentation handoff before the first production lot ships.
Frequently asked questions
How many panelists do we need for a wear test?
For directional screening between two or three candidate formulas, 20–30 local panelists is workable. If the data is intended to support an external marketing claim, plan for a larger, documented consumer study — 50–100+ — with a written protocol a third party could audit.
Can a blotter test replace the skin wear test?
No. Blotters are excellent for screening opening impact and dry-down quality, but they cannot predict projection or longevity on skin, and they do not reflect local climate or consumer expectation. Use blotters to eliminate, skin testing to decide.
Do we need separate panels for France and Germany?
At minimum, recruit panelists from each market and run the questionnaire in the local language, because category vocabulary and performance expectations differ. If your positioning is broadly the same in both markets, one design with two recruitment cells is usually sufficient; if the positioning differs, run them separately.
Can we advertise a specific number of hours of longevity?
We strongly advise against a uniform hour claim. Perception varies with skin type, climate, dose and activity, and a fixed number invites direct contradiction in reviews. Publish graded performance language that your panel report supports, plus a short, honest note about variability.
Does wear-test data replace the CPSR or the allergen labelling?
No. Panel data supports performance and sensory claims only. Safety documentation — CPSR, PIF, CPNP notification, allergen labelling under the current EU rules — is a separate obligation and should be finalised alongside, not instead of, your testing programme.
Next step
If you are preparing a France or Germany launch and want a wear-test panel scoped against your performance tier, benchmark and claim list, send us your brief. Include the target markets, the number of SKUs and formats, your positioning, your packaging direction and your target launch window — that is the information that shortens a quote fastest. Request a Quote and we will come back with a panel design, a documentation checklist and a realistic timeline.
This article is informational only and does not constitute legal or regulatory advice. Confirm obligations with your EU Responsible Person and a qualified safety assessor.
LAEYO
Hi, I'm your LAEYO representative, hope you like this blog post.
With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.